- 3 Growth Stocks to Add to Your Roster
May 12, 2026
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.
Deciphering which businesses can sustain their high growth rates is a challenge for even the most seasoned professionals, which is why we started StockStory. Keeping that in mind, here are three growth stocks where the best is yet to come.
Alphabet (GOOGL)
One-Year Revenue Growth: +17.5%
Started by Stanford students Larry Page and Sergey Brin in a Menlo Park garage, Alphabet (NASDAQ:GOOGL) is the parent company of the eponymous Google Search engine, Google Cloud Platform, and YouTube.
Why Is GOOGL a Good Business?
Alphabet’s dominant Google Search sits on the pantheon of the best businesses ever. This is reflected in its robust long-term revenue growth and elite operating margin. The company’s profit margins have become even higher over time, speaking to its scale advantages and operating efficiency not only in its core Search business but also in Google Cloud Platform and YouTube. Revenue growth and increasing operating margins are the key ingredients for strong EPS growth. Google has these, and when also factoring in its share repurchases, you can see why EPS has exploded over the long term.
Alphabet is trading at $396.80 per share, or 31.7x forward price-to-earnings. Is now a good time to buy? See for yourself in our in-depth research report, it’s free.
Boston Scientific (BSX)
One-Year Revenue Growth: +17.4%
Founded in 1979 with a mission to advance less-invasive medicine, Boston Scientific (NYSE:BSX) develops and manufactures medical devices used in minimally invasive procedures across cardiovascular, urological, neurological, and gastrointestinal specialties.
Why Are We Positive On BSX?
Average organic revenue growth of 15.7% over the past two years demonstrates its ability to expand independently without relying on acquisitions Additional sales over the last five years increased its profitability as the 24.2% annual growth in its earnings per share outpaced its revenue Free cash flow margin increased by 9.1 percentage points over the last five years, giving the company more capital to invest or return to shareholders
Boston Scientific’s stock price of $56.33 implies a valuation ratio of 16.2x forward P/E. Is now the time to initiate a position? Find out in our full research report, it’s free.
Bowhead Specialty (BOW)
One-Year Revenue Growth: +27.7%
Named after the Arctic bowhead whale known for navigating challenging waters, Bowhead Specialty Holdings (NYSE:BOW) is a specialty insurance company that provides customized coverage for complex and high-risk commercial sectors.
Story Continues
Why Are We Backing BOW?
Net premiums earned surged by 33.5% annually over the past two years, reflecting strong market share gains this cycle Earnings per share grew by 42.9% annually over the last three years and trumped its peers Annual book value per share growth of 29.1% over the past two years was outstanding, reflecting strong capital accumulation this cycle
At $26.34 per share, Bowhead Specialty trades at 1.6x forward P/B. Is now the right time to buy? See for yourself in our comprehensive research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
View Comments
- [Latest] Global Flexible Endoscope Market Size/Share Worth USD 22.7 Billion by 2035 at a 6% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
May 11, 2026
Custom Market Insights
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Flexible Endoscope Market size & share revenue was valued at approximately USD 12.7 Billion in 2025 and is expected to reach USD 13.5 Billion in 2026 and is expected to reach around USD 22.7 Billion by 2035, at a CAGR of 6% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Olympus Corporation, Cook Medical Inc., Becton Dickinson and Company, Boston Scientific Corporation, Cantel Medical Corporation, Conmed Corporation, B. Braun SE, EndoMed Systems GmbH, Firefly Global, Fujifilm Holdings Corporation, H.W.Andersen Products Ltd., Hoya Corporation, Intuitive Surgical Inc., Karl Storz SE & Co. KG, Machida Endoscope Co. Ltd, Ambu A/S and others.
Austin, TX, USA, May 11, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Flexible Endoscope Market Size, Trends and Insights By Product (Bronchoscopes, Laparoscopes, Otoscopes, Laryngoscopes, Cystoscopes, Ureteroscopes, Arthroscopes, Nasopharyngoscopes, Neuroendoscopes, Rhinoscopes, Gastrointestinal Endoscopes, Hysteroscopes, Gynecology Endoscopes), By End Use (Hospitals, Outpatient Facilities), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2026 – 2035” in its research database.
According to the latest research study, the global Flexible Endoscope Market was valued at approximately USD 12.7 billion in 2025 and is expected to reach USD 13.5 billion in 2026, with a projected value of around USD 22.7 billion by 2035, at a compound annual growth rate (CAGR) of about 6% during the forecast period from 2026 to 2035.
Click Here to Access a Free Sample Report of the Global Flexible Endoscope Market @ https://www.healthcareforesights.com/request-customization?reportId=1002Flexible Endoscope Market 2026 – 2035
Flexible Endoscope Market Revenue and Trends
A flexible endoscope is a medical tool that looks inside the body, finds problems, and treats them without making big cuts or through small openings.It has a long, thin, and flexible insertion tube that contains a light source, a high-resolution camera or a fiber-optic imaging system, and one or more working channels for instruments used in biopsy, suction, irrigation, or therapeutic procedures.. Flexible endoscopes' ability to bend and navigate through complex anatomical pathways makes them perfect for examining different parts of the body, such as the gastrointestinal tract, respiratory system, urinary tract, and other delicate structures. They are involved with many procedures including gastroscopy, colonoscopy, bronchoscopy, and cystoscopy and are central to the whole process of minimally invasive diagnostics and treatment that depends on real-time visualization with fair patient comfort level, quicker recovery, and lower risk compared to traditional surgical techniques. The market growth is driven by several factor such as increasing prevalence of cancer, growing product launch and increasing investment in emerging markets by the key market players.
Story Continues
Request a Customized Copy of the Flexible Endoscope Market Report @https://www.healthcareforesights.com/request-sample?reportId=1002
What factors significantly contribute to the growth of the flexible endoscope market?
The flexible endoscopes market is experiencing significant growth due to an amalgamation of various factors like clinical, technological, economic, and regulatory which in turn are increasing the number of procedures and speeding up the adoption of equipment across the different healthcare sectors.
The global burden of diseases affecting the gastrointestinal and respiratory systems which are very painful and expensive to treat as they include conditions like GERD, colorectal cancer, inflammatory bowel disease, COPD, and lung infections is also one of the main factors that is driving the endoscope market. Controlling and monitoring the diseases through endoscopic means requires frequent diagnosis and monitoring. Besides this, the industry is also turning to the less challenging method of open surgeries, i.e. flexible endoscopy, to do less harm to the patients and cut hospital stays and treatment costs.
In addition, medical science is advancing rapidly in technology, which is also a major factor driving the endoscope market. The introduction of high-definition and 4K imaging, along with better visualization techniques, AI-powered lesion detection, and advanced tissue imaging (optical biopsy), improves diagnostic accuracy and builds clinical confidence, making hospitals more likely to upgrade or replace their old systems. More focus on infection control and patient safety has also led to faster adoption of single-use flexible endoscopes and endoscopes with disposable parts, thus creating new revenue streams and penetrating high-risk procedures more effectively.
(A free sample of the Flexible Endoscope report is available upon request; please contact us for more information.)
Our Free Sample Report Consists of the following:
The updated report for 2026 includes an introduction, an overview, and an in-depth industry analysis. Provide detailed chapter-by-chapter guidance on the Request. Updated Regional Analysis with a Graphical Representation of Size, Share, and Trends for the Year 2026 Includes tables and figures that have been updated. The most recent version of the report includes the Top Market Players, their Business Strategies, Sales Volume, and Revenue Analysis Healthcare Foresights (HEALTHCARE FORESIGHTS) research methodology
Request a Customized Copy of the Flexible Endoscope Market Report @https://www.healthcareforesights.com/reports/flexible-endoscope-market
Segment Insight
By Product
The gynecology endoscopes segment is growing at a significant rate over the projected period. The growing number of gynecological disorders, such as uterine fibroids, endometriosis, polycystic ovary syndrome (PCOS), and cancers of the cervix and uterus, is the main reason for the growth of this market. Patients suffering from such diseases invariably require the diagnostic and therapeutic endoscopic interventions of the highest order. As awareness of women’s health issues grows and screening and early intervention programs expand, mere reliance on flexible endoscopes for procedures translates into a large volume of procedures and, consequently, sales of the related equipment.
Request a Customized Copy of the Flexible Endoscope Market Report @ https://www.healthcareforesights.com/reports/flexible-endoscope-market
Key questions answered in this report:
What is the size of the Flexible Endoscope market, and what is its expected growth rate? What are the primary driving factors that push the Flexible Endoscope market forward? What are the Flexible Endoscope Industry's top companies? What are the different categories that the Flexible Endoscope Market caters to? What will be the fastest-growing segment or region? In the value chain, what role do key players play? What is the procedure for getting a free copy of the sample report for the Flexible Endoscope market and company profiles?
Buy Now Flexible Endoscope Market Report @ https://www.healthcareforesights.com/checkout/1002
Key Offerings:
Market Share, Size & Forecast by Revenue | 2026−2035 Market Dynamics – Growth Drivers, Restraints, Investment Opportunities, and Leading Trends Market Segmentation – A detailed analysis by Types of Services, by End-User Services, and by regions Competitive Landscape – Top Key Vendors and Other Prominent Vendors
Buy this Premium Flexible Endoscope Research Report | Fast Delivery Available - [220+ Pages] @ https://www.healthcareforesights.com/reports/flexible-endoscope-market
Regional Insights
The flexible endoscope market has been dominated by North America. The North America region has also been supported by advanced healthcare infrastructure, government initiatives that are conducive to healthcare, and optimum treatment coverage.
Besides, the Asia-Pacific market has the highest growth rate in the flexible endoscope market. The major influencing factor for this upsurge is the heavy burden of the target illnesses, and the expectation of a significant patient group is also going to help the growth of the area. The healthcare infrastructure in the region is improving, with increased investment from market players primarily driven by the booming demand for medical devices in the APAC region, leading to a certain degree of growth.
Request a Customized Copy of the Flexible Endoscope Market Report @ https://www.healthcareforesights.com/reports/flexible-endoscope-market
We customize your report to align with your specific research requirements. Inquire with our sales team about customizing your report.)
Still Looking for More Information? Do you want data for inclusion in magazines, case studies, research papers, or media?
Email Directly Here with Detailed Information: support@custommarketinsights.com
Browse the full “Flexible Endoscope Market Size, Trends and Insights By Product (Bronchoscopes, Laparoscopes, Otoscopes, Laryngoscopes, Cystoscopes, Ureteroscopes, Arthroscopes, Nasopharyngoscopes, Neuroendoscopes, Rhinoscopes, Gastrointestinal Endoscopes, Hysteroscopes, Gynecology Endoscopes), By End Use (Hospitals, Outpatient Facilities), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2026 – 2035” Report at https://www.healthcareforesights.com/reports/flexible-endoscope-market
Report Scope
Feature of the Report Details Market Size in 2026 USD 13.5 billion Projected Market Size in 2035 USD 22.7 billion Market Size in 2025 USD 12.7 billion CAGR Growth Rate 6% CAGR Base Year 2025 Forecast Period 2026-2035 Key Segment By Product, End Use and Region Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends Regional Scope North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America Buying Options Request tailored purchasing options to fulfil your requirements for research.
Recent Developments
In August 2024, KARL STORZ United States, a global leader in Operating Room (OR) integration, teamed up with FUJIFILM Healthcare Americas Corporation (Fujifilm), a major maker of endoscopic imaging and endosurgical products, to provide a wide range of solutions for both endoscopists and surgeons. The two companies will together promote Fujifilm’s exceptional flexible gastrointestinal (GI) endoscopes and KARL STORZ’s unmatched OR integration solutions. The partnership between Fujifilm and KARL STORZ will help upgrade surgical ORs, routine and interventional hospital GI suites, and ambulatory surgery centers (ASCs) with innovative OR integration and state-of-the-art flexible endoscopes in areas where most GI and surgical OR procedures are done. (Source: https://www.biopharmaapac.com/news/77/5181/karl-storz-and-fujifilm-healthcare-partner-to-enhance-gi-endoscopy-and-or-integration.html)
Click Here to Access a Free Sample Report of the Global Flexible Endoscope Market @ https://www.healthcareforesights.com/reports/flexible-endoscope-market
Spectacular Deals
Comprehensive coverage Maximum number of market tables and figures The subscription-based option is offered. Best price guarantee Free 35% or 60 hours of customization. Free post-sale service assistance. 25% discount on your next purchase. Service guarantees are available. A personalized market brief by the author.
Browse More Related Reports:
Henatologic Malignancies Testing Market
US Clinical Trial Supplies Market
Ear Health Market
Fluorescent In Situ Hybridization Probe Market
Laboratory Equipment Services Market
Synthetic Bone Graft Substitutes Market
Japan Epigenetics Market
US Cell-Based Assays Market
Therapeutic Plasma Exchange Market
Therapeutic Apheresis MarketNorth America Flexible Endoscope Market Size 2025 to 2035 (USD Billion)
List of the prominent players in the Flexible Endoscope Market:
Olympus Corporation Cook Medical Inc. Becton Dickinson and Company Boston Scientific Corporation Cantel Medical Corporation Conmed Corporation B. Braun SE EndoMed Systems GmbH Firefly Global Fujifilm Holdings Corporation H.W. Andersen Products Ltd. Hoya Corporation Intuitive Surgical Inc. Karl Storz SE & Co. KG Machida Endoscope Co. Ltd Ambu A/S Others
The Flexible Endoscope Market is segmented as follows:
By Product
Bronchoscopes Laparoscopes Otoscopes Laryngoscopes Cystoscopes Ureteroscopes Arthroscopes Nasopharyngoscopes Neuroendoscopes Rhinoscopes Gastrointestinal Endoscopes Hysteroscopes Gynecology Endoscopes
By End Use
Hospitals Outpatient Facilities
Click Here to Get a Free Sample Report of the Global Flexible Endoscope Market @ https://www.healthcareforesights.com/reports/flexible-endoscope-market
Regional Coverage:
North America
U.S. Canada Mexico Rest of North America
Europe
Germany France U.K. Russia Italy Spain Netherlands Rest of Europe
Asia Pacific
China Japan India New Zealand Australia South Korea Taiwan Rest of Asia Pacific
The Middle East & Africa
Saudi Arabia UAE Egypt Kuwait South Africa Rest of the Middle East & Africa
Latin America
Brazil Argentina Rest of Latin America
This Flexible Endoscope Market Research/Analysis Report Contains Answers to the following Questions.
Which Trends Are Causing These Developments? Who Are the Global Key Players in This Flexible Endoscope Market? What are the company profiles, product information, and contact details for these key players? What Was the Global Market Status of the Flexible Endoscope Market? What Was the Capacity, Production Value, Cost, and PROFIT of the Flexible Endoscope Market? What Is the Current Market Status of the Flexible Endoscope Industry? What's the market's competition in this industry, both company-wise and country-wise? What is the market analysis of the flexible endoscope market, considering its applications and types? What Are Projections of the Global Flexible Endoscope Industry Considering Capacity, Production, and Production Value? What Will Be the Estimate of Cost and Profit? What Will Be the Market Share, Supply, and Consumption? What about imports and exports? What is a Flexible Endoscope market chain analysis of upstream raw materials and downstream industries? What is the economic impact on the Flexible Endoscope industry? What are Global Macroeconomic Environment Analysis Results? What Are Global Macroeconomic Environment Development Trends? What Are the Market Dynamics of the Flexible Endoscope Market? What Are Challenges and Opportunities? What Should Be Entry Strategies, Countermeasures to Economic Impact, and Marketing Channels for the Flexible Endoscope Industry?
Click Here to Access a Free Sample Report of the Global Flexible Endoscope Market @ https://www.healthcareforesights.com/reports/flexible-endoscope-market
Reasons to Purchase Flexible Endoscope Market Report
The Flexible Endoscope Market Report gives both qualitative and quantitative analysis of the market by looking at economic and non-economic factors. Flexible Endoscope: The market report outlines the market value (in USD) data for each segment and sub-segment. This report indicates the region and segment expected to witness the fastest growth and dominate the market. Flexible Endoscope Market Analysis by geography highlights the consumption of the product/service in the region and indicates the factors affecting the market within each region. The competitive landscape incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled. Extensive company profiles comprise a company overview, company insights, product benchmarking, and SWOT analysis for the major market players. Recent developments, including growth opportunities and drivers, as well as challenges and restraints in both emerging and developed regions, shape the industry's current and future market outlook. Flexible Endoscope Market: Includes in-depth market analysis from various perspectives through Porter's five forces analysis and offers an overview of the market through the value chain.
Reasons for the Research Report
The study provides a thorough overview of the global Flexible Endoscope market. Compare your performance to that of the market as a whole.
Aim to maintain competitiveness while innovations from established leaders drive market growth.
Buy this Premium Flexible Endoscope Research Report | Fast Delivery Available - [220+ Pages] @ https://www.healthcareforesights.com/reports/flexible-endoscope-market
What does the report include?
Drivers, restrictions, and opportunities are among the qualitative elements covered in the worldwide Flexible Endoscope market analysis.
The report covers the competitive environment of current and potential participants in the Flexible Endoscope market, along with their strategic product development ambitions.
This study conducts a qualitative and quantitative analysis of the Flexible Endoscope market based on the component, application, and industry vertical. Additionally, the report provides comparable data for the key regions.
The report provides actual market sizes and forecasts for each segment mentioned above.
Who should buy this report?
Participants and stakeholders in the worldwide flexible endoscope market should find this report useful. The research will be useful to all market participants in the Flexible Endoscope industry.
Managers in the Flexible Endoscope sector are interested in publishing up-to-date and projected data about the worldwide Flexible Endoscope market.
Governmental agencies, regulatory bodies, decision-makers, and organizations want to invest in Flexible Endoscope products' market trends.
Analysts, researchers, educators, strategy managers, and government organizations seek market insights to develop plans.
Request a Customized Copy of the Flexible Endoscope Market Report @ https://www.healthcareforesights.com/reports/flexible-endoscope-market
About Healthcare Foresights:
Healthcare Foresights is a market research and advisory company delivering business insights and market research reports to large, small, and medium-scale enterprises. We assist clients with strategies and business policies and regularly work towards achieving sustainable growth in their respective domains.
Healthcare Foresights is a one-stop solution for data collection and investment advice. Our company's expert analysis digs out essential factors that help us understand the significance and impact of market dynamics. The professional experts advise clients on aspects such as strategies for future estimation, forecasting, opportunities to grow, and consumer surveys.
Follow Us: LinkedIn | Twitter | Facebook | Instagram
Contact Us:
Frank Gittens
CMI Consulting LLC
701 Tillery Street Unit 12-1333
Austin, Texas 78702
United States
USA: +1 737-734-2707
APAC: +91 20 46022736
WhatsApp No : +1 801 639 9061
Email: support@healthcareforesights.com
Blog: https://www.healthcareforesights.com/
Buy this Premium Flexible Endoscope Research Report | Fast Delivery Available - [220+ Pages] @ https://www.healthcareforesights.com/reports/flexible-endoscope-market
View Comments
- BSX Q1 Neuromodulation Sales Rise 15% Y/Y: What Lies Behind the Growth?
May 8, 2026
Boston Scientific’s BSX Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. This segment reflects the company’s long-term commitment to gain leadership through innovation and targeted acquisitions, along with strategies to sustain and accelerate growth across neuromodulation therapies.
Neuromodulation delivered a strong quarter, with organic sales increasing 15% and the comprehensive portfolio posting low double-digit growth. The pain management business grew in the mid-teens, supported partially by a strong contribution from the acquisition of Nalu (completed in late January 2026).
Intracept continued to gain momentum, driven by compelling five-year clinical data demonstrating its long-term efficacy and cost-effectiveness in treating chronic low back pain. Within DBS, adoption of the Cartesia X leads remained strong, while the Illumina 3D programming algorithm saw accelerating uptake across the United States.
Boston Scientific continues to invest in neuromodulation platforms while strengthening its commercial capabilities. The Neuromodulation segment showed improvement, supported by organic contributions from acquisitions such as Relievant and Axonics in 2025. Management expects the Neuromodulation business to grow faster than the broader market over time.
Updates on BSX’s Neuromodulation Competitors
NeuroPace NPCE delivered a strong neuromodulation business performance in fourth-quarter 2025, driven by continued adoption of its responsive neurostimulation (RNS) platform for drug-resistant epilepsy. The company also accelerated development of AI-enabled neuromodulation tools like Seizure ID — an AI-driven platform designed to analyze intracranial EEG recordings, identify seizure activity, and improve physician workflow efficiency.
Medtronic's MDT Neuromodulation business reported 4% growth in the fiscal third quarter, with the ongoing rollout of its Inceptiv spinal cord stimulation (SCS) system and BrainSense adaptive DBS (aDBS) platforms. Inceptiv spinal cord stimulation system is the smallest and thinnest closed-loop SCS device available and offers best-in-class MRI compatibility. With neuromodulation systems’ adoption expanding across major geographies, the company remains well positioned for sustained momentum and long-term leadership in neuromodulation and neurosurgical innovation.
BSX Stock Price Performance
Shares of Boston Scientific have lost 45.2% over the past year compared with the industry’s decline of 29%. The S&P 500 composite has grown 35.4% in the same period.
Story Continues
Zacks Investment Research
Image Source: Zacks Investment Research
Boston Scientific’s Valuation
From a valuation standpoint, BSX trades at a forward 12-month price-to-earnings ratio (P/E) of 3.76X, above the industry median of 3.09X.Zacks Investment Research
Image Source: Zacks Investment Research
BSX Stock Consensus Estimate Trend
The Zacks Consensus Estimate for BSX’s earnings has moved south 2% over the past 30 days.Zacks Investment Research
Image Source: Zacks Investment Research
BSX stock currently has a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Boston Scientific Corporation (BSX) : Free Stock Analysis Report
Medtronic PLC (MDT) : Free Stock Analysis Report
NeuroPace, Inc. (NPCE) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- Penumbra, Inc. Reports First Quarter 2026 Financial Results
May 6, 2026
ALAMEDA, Calif., May 6, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2026.Penumbra, Inc. (PRNewsfoto/Penumbra, Inc.)
Revenue of $374.8 million in the first quarter of 2026, an increase of 15.6% compared to the first quarter of 2025. Global thrombectomy revenue of $253.9 million in the first quarter of 2026, an increase of 12.1% compared to the first quarter of 2025. Global embolization and access revenue of $120.8 million in the first quarter of 2026, an increase of 23.8% compared to the first quarter of 2025. Gross profit margin of 67.6% in the first quarter of 2026, an increase of 1.0% compared to the first quarter of 2025. Total operating expenses of $215.2 million in the first quarter of 2026, comprised of R&D of $22.4 million and SG&A of $192.8 million, which includes $9.4 million of acquisition-related expenses associated with the pending acquisition of Penumbra, Inc. by Boston Scientific Corporation. Income from operations of $38.2 million and net income of $32.6 million in the first quarter of 2026.
Full Year 2026 Financial Outlook and Webcast and Conference Call Information Given the pending acquisition of Penumbra, Inc. by Boston Scientific Corporation (NYSE: BSX), the Company will not be providing financial guidance for the full year 2026 or hosting a conference call to discuss financial results for the three months ended March 31, 2026.
About Penumbra Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn, and X.
Forward-Looking Statements Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: the risk that the pending acquisition by Boston Scientific Corporation will not be completed in the expected timeframe or at all, including the risk that required regulatory approvals will not be obtained; potential adverse effects to our business during the pendency of the acquisition, such as employee departures or diversion of management's attention from our business; failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory or other assets; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on February 25, 2026. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.
Story Continues
Penumbra, Inc.
Condensed Consolidated Balance Sheets
(unaudited)
(in thousands) March 31, 2026 December 31, 2025 Assets Current assets: Cash and cash equivalents $ 241,289 $ 186,897 Marketable investments 374,371 357,919 Accounts receivable, net 183,295 190,021 Inventories 438,539 431,549 Prepaid expenses and other current assets 37,912 50,298 Total current assets 1,275,406 1,216,684 Property and equipment, net 134,059 117,436 Operating lease right-of-use assets 170,273 173,587 Finance lease right-of-use assets 25,209 25,972 Intangible assets, net 5,946 6,186 Goodwill 166,589 166,750 Deferred taxes 79,972 79,188 Other non-current assets 40,984 40,716 Total assets $ 1,898,438 $ 1,826,519 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 43,658 $ 34,736 Accrued liabilities 151,543 132,163 Current operating lease liabilities 14,144 13,841 Current finance lease liabilities 2,386 2,393 Total current liabilities 211,731 183,133 Non-current operating lease liabilities 179,424 182,751 Non-current finance lease liabilities 20,221 20,714 Other non-current liabilities 13,250 12,318 Total liabilities 424,626 398,916 Stockholders' equity: Common stock 39 39 Additional paid-in capital 1,201,423 1,185,525 Accumulated other comprehensive income 2,075 4,348 Retained earnings 270,275 237,691 Total stockholders' equity 1,473,812 1,427,603 Total liabilities and stockholders' equity $ 1,898,438 $ 1,826,519
Penumbra, Inc.
Condensed Consolidated Statements of Operations
(unaudited)
(in thousands, except share and per share amounts) Three Months Ended March 31, 2026 2025 Revenue $ 374,758 $ 324,140 Cost of revenue 121,347 108,257 Gross profit 253,411 215,883 Operating expenses: Research and development 22,382 22,077 Sales, general and administrative 192,795 153,456 Total operating expenses 215,177 175,533 Income from operations 38,234 40,350 Interest and other income, net 3,454 3,508 Income before income taxes 41,688 43,858 Provision for income taxes 9,104 4,635 Net income $ 32,584 $ 39,223 Net income per share: Basic $ 0.83 $ 1.02 Diluted $ 0.82 $ 1.00 Weighted average shares outstanding: Basic 39,275,424 38,562,191 Diluted 39,543,780 39,163,428
Penumbra, Inc.
Reconciliation of Revenue Growth by Geographic Regions
(unaudited)
(in thousands, except for percentages) Three Months Ended March 31, Change 2026 2025 $ % United States $ 296,387 $ 256,860 $ 39,527 15.4 % International 78,371 67,280 11,091 16.5 % Total $ 374,758 $ 324,140 $ 50,618 15.6 %
Penumbra, Inc.
Reconciliation of Revenue Growth by Product Categories
(unaudited)
(in thousands, except for percentages) Three Months Ended March 31, Change 2026 2025 $ % Thrombectomy $ 253,917 $ 226,544 $ 27,373 12.1 % Embolization and Access 120,841 97,596 23,245 23.8 % Total $ 374,758 $ 324,140 $ 50,618 15.6 %
Investor Relations Penumbra, Inc.
investors@penumbrainc.comCision
View original content to download multimedia:https://www.prnewswire.com/news-releases/penumbra-inc-reports-first-quarter-2026-financial-results-302764359.html
View Comments
- Do Boston Scientific's (NYSE:BSX) Earnings Warrant Your Attention?
May 6, 2026
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks' without any revenue, let alone profit. Sometimes these stories can cloud the minds of investors, leading them to invest with their emotions rather than on the merit of good company fundamentals. Loss making companies can act like a sponge for capital - so investors should be cautious that they're not throwing good money after bad.
If this kind of company isn't your style, you like companies that generate revenue, and even earn profits, then you may well be interested in Boston Scientific (NYSE:BSX). While profit isn't the sole metric that should be considered when investing, it's worth recognising businesses that can consistently produce it.
AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.
How Quickly Is Boston Scientific Increasing Earnings Per Share?
Generally, companies experiencing growth in earnings per share (EPS) should see similar trends in share price. That means EPS growth is considered a real positive by most successful long-term investors. Recognition must be given to the that Boston Scientific has grown EPS by 60% per year, over the last three years. That sort of growth rarely ever lasts long, but it is well worth paying attention to when it happens.
One way to double-check a company's growth is to look at how its revenue, and earnings before interest and tax (EBIT) margins are changing. EBIT margins for Boston Scientific remained fairly unchanged over the last year, however the company should be pleased to report its revenue growth for the period of 17% to US$21b. That's encouraging news for the company!
The chart below shows how the company's bottom and top lines have progressed over time. For finer detail, click on the image.NYSE:BSX Earnings and Revenue History May 6th 2026
See our latest analysis for Boston Scientific
In investing, as in life, the future matters more than the past. So why not check out this freeinteractive visualization of Boston Scientific's forecast profits?
Are Boston Scientific Insiders Aligned With All Shareholders?
We would not expect to see insiders owning a large percentage of a US$84b company like Boston Scientific. But thanks to their investment in the company, it's pleasing to see that there are still incentives to align their actions with the shareholders. Notably, they have an enviable stake in the company, worth US$158m. While that is a lot of skin in the game, we note this holding only totals to 0.2% of the business, which is a result of the company being so large. This still shows shareholders there is a degree of alignment between management and themselves.
Story Continues
Should You Add Boston Scientific To Your Watchlist?
Boston Scientific's earnings per share growth have been climbing higher at an appreciable rate. This level of EPS growth does wonders for attracting investment, and the large insider investment in the company is just the cherry on top. At times fast EPS growth is a sign the business has reached an inflection point, so there's a potential opportunity to be had here. So based on this quick analysis, we do think it's worth considering Boston Scientific for a spot on your watchlist. While we've looked at the quality of the earnings, we haven't yet done any work to value the stock. So if you like to buy cheap, you may want to check if Boston Scientific is trading on a high P/E or a low P/E, relative to its industry.
While opting for stocks without growing earnings and absent insider buying can yield results, for investors valuing these key metrics, here is a carefully selected list of companies in the US with promising growth potential and insider confidence.
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
View Comments
- SNN vs. BSX: Which Stock Is the Better Value Option?
May 5, 2026
Investors interested in Medical - Products stocks are likely familiar with Smith & Nephew (SNN) and Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.
Smith & Nephew has a Zacks Rank of #2 (Buy), while Boston Scientific has a Zacks Rank of #4 (Sell) right now. This means that SNN's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. But this is just one piece of the puzzle for value investors.
Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.
The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.
SNN currently has a forward P/E ratio of 13.52, while BSX has a forward P/E of 16.84. We also note that SNN has a PEG ratio of 0.96. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. BSX currently has a PEG ratio of 1.04.
Another notable valuation metric for SNN is its P/B ratio of 2.48. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. By comparison, BSX has a P/B of 3.24.
These are just a few of the metrics contributing to SNN's Value grade of A and BSX's Value grade of C.
SNN stands above BSX thanks to its solid earnings outlook, and based on these valuation figures, we also feel that SNN is the superior value option right now.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Smith & Nephew SNATS, Inc. (SNN) : Free Stock Analysis Report
Boston Scientific Corporation (BSX) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- Boston Scientific announces participation in Bernstein's 42nd Annual Strategic Decisions Conference and conference call discussing second quarter 2026 results
May 4, 2026
MARLBOROUGH, Mass., May 4, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Bernstein's 42nd Annual Strategic Decisions Conference on Wednesday, May 27, 2026. Mike Mahoney, chairman and chief executive officer, and Janar Sathananthan, M.D., chief medical officer, Interventional Cardiology Therapies, will participate in a 50-minute question-and-answer session with the host analyst at approximately 8:00 a.m. ET.Boston Scientific Corporation (PRNewsFoto/Boston Scientific Corporation) (PRNewsFoto/Boston Scientific Corporation) (PRNewsfoto/Boston Scientific Corporation)
Additionally, the company will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2026, on Wednesday, July 29, 2026, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney and Jon Monson, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the second quarter 2026 on July 29 prior to the conference call.
A live webcast and replay for each event will be accessible at https://investors.bostonscientific.com. The replays will be available approximately one hour following the completion of each event.
About Boston Scientific
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and follow us on LinkedIn.
CONTACTS:
Chanel Hastings
Media Relations
+1 (508) 382-0288
Chanel.Hastings@bsci.com
Lauren Tengler
Investor Relations
+1 (508) 683-4479
BSXInvestorRelations@bsci.comCision
View original content to download multimedia:https://www.prnewswire.com/news-releases/boston-scientific-announces-participation-in-bernsteins-42nd-annual-strategic-decisions-conference-and-conference-call-discussing-second-quarter-2026-results-302760793.html
View Comments
- Boston Scientific Lawsuits Put Electrophysiology Outlook And Valuation In Focus
May 2, 2026
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide.
Multiple securities class action lawsuits have been filed against Boston Scientific (NYSE:BSX), alleging misleading statements about the sustainability of U.S. electrophysiology growth. The cases focus on disclosures related to a key business segment and whether investors were given an accurate view of growth prospects. Several court ordered and attorney set deadlines are approaching for shareholders who may wish to participate in these actions.
Boston Scientific is a large medical device company with exposure to electrophysiology, where products support the diagnosis and treatment of cardiac rhythm disorders. For investors, any legal challenge tied to disclosures in such a segment can draw attention to how growth expectations are framed and communicated. This development arrives as medical technology companies continue to face scrutiny around clinical data, marketing claims, and segment specific performance commentary.
For shareholders in NYSE:BSX, these lawsuits raise questions about potential legal costs and future disclosure practices. The approaching deadlines mean investors may want to review their holdings, past company statements on U.S. electrophysiology growth, and any information from counsel to decide whether further action is appropriate.
Stay updated on the most important news stories for Boston Scientific by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Boston Scientific.NYSE:BSX 1-Year Stock Price Chart
Is Boston Scientific's balance sheet strong enough for future acquisitions? Dive into our detailed financial health analysis.
Quick Assessment
✅ Price vs Analyst Target: At US$56.50 versus a consensus target of US$85.19, the price sits about 34% below analyst expectations. ✅ Simply Wall St Valuation: Simply Wall St currently assesses Boston Scientific as undervalued, trading about 47.6% below its estimated fair value. ❌ Recent Momentum: The 30 day return of roughly 8.9% decline signals recent pressure on the share price.
There is only one way to know the right time to buy, sell or hold Boston Scientific. Head to Simply Wall St's company report for the latest analysis of Boston Scientific's Fair Value.
Key Considerations
📊 The lawsuits focus on U.S. electrophysiology disclosures, so you may want to reassess how much of your thesis relies on this segment. 📊 Watch legal updates, any changes to guidance on electrophysiology growth, and how the P/E of 23.6 compares with the 23.6 industry average over time. ⚠️ Simply Wall St flags high debt as a risk, which could matter if legal costs or settlements affect future balance sheet flexibility.
Story Continues
Dig Deeper
For the full picture including more risks and rewards, check out the complete Boston Scientific analysis. Alternatively, you can check out the community page for Boston Scientific to see how other investors believe this latest news will impact the company's narrative.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include BSX.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments
- Boston Scientific Corporation (BSX): Billionaire Tom Steyer Is Loading Up on This Stock
May 2, 2026
We just covered Billionaire Tom Steyer’s 10 Stock Picks with Huge Upside Potential and Boston Scientific Corporation (NYSE:BSX) ranks 9th on this list.
Boston Scientific Corporation (NYSE:BSX) has consistently featured in the 13F portfolio of Farallon Capital since the third quarter of 2020. Back then, this position comprised just under 8.3 million shares. The fund steadily added to this stake until the fourth quarter of 2021, growing it to over 16.8 million shares. Thereafter, it started trimming the stock. Filings for the fourth quarter of 2025 show that the fund owned 7.4 million shares in the firm, up more than 56% compared to filings for the previous quarter. The company develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.
READ ALSO: 15 Under-the-Radar Picks from David Einhorn That Are Quietly Dominating 2026.Piper Sandler Maintains Overweight Rating on Blue Owl Capital (OWL)
Boston Scientific Corporation (NYSE:BSX) is attracting interest from elite investors due to crown jewel products, which dominated headlines at the Heart Rhythm 2026 conference. The first of these was FARAPULSE PFA. New clinical data demonstrated that this device is superior to traditional antiarrhythmic drugs for treating persistent atrial fibrillation. The second was the success of WATCHMAN. The CHAMPION-AF study recently confirmed that the WATCHMAN device is a safe and effective first-line alternative to blood thinners, which opens up a significantly larger patient market. In its Q1 2026 earnings report, Boston Scientific beat revenue expectations, $5.20 billion versus $5.17 billion, but lowered its full-year guidance.
While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 14 Best Defensive Stocks to Invest In Now and 14 Best Low Risk High Growth Stocks to Buy Right Now.
Disclosure: None. Follow Insider Monkey on Google News.
View Comments
- Wall Street Analysts Think Boston Scientific (BSX) Is a Good Investment: Is It?
May 1, 2026
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?
Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Boston Scientific (BSX).
Boston Scientific currently has an average brokerage recommendation (ABR) of 1.32, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 31 brokerage firms. An ABR of 1.32 approximates between Strong Buy and Buy.
Of the 31 recommendations that derive the current ABR, 24 are Strong Buy and four are Buy. Strong Buy and Buy respectively account for 77.4% and 12.9% of all recommendations.
Brokerage Recommendation Trends for BSXBroker Rating Breakdown Chart for BSX
Check price target & stock forecast for Boston Scientific here>>>
While the ABR calls for buying Boston Scientific, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.
Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation.
This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.
With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near-term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision.
Zacks Rank Should Not Be Confused With ABR
Although both Zacks Rank and ABR are displayed in a range of 1--5, they are different measures altogether.
The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
Story Continues
Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.
In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.
Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.
Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.
Is BSX Worth Investing In?
Looking at the earnings estimate revisions for Boston Scientific, the Zacks Consensus Estimate for the current year has declined 2.2% over the past month to $3.38.
Analysts' growing pessimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates lower, could be a legitimate reason for the stock to plunge in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #4 (Sell) for Boston Scientific. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Therefore, it could be wise to take the Buy-equivalent ABR for Boston Scientific with a grain of salt.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Boston Scientific Corporation (BSX) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
